Sarepta Therapeutics (SRPT)

• Market cap: $5.3B
• 1 day: -0.28%
• 5 days: 5.02%
• 1 month: -46.93%
• 3 months: -54.42%
• 6 months: -56.71%
• Year to date: -56.65%
• 1 year: -54.37%
• 5 years: -54.62%
• 10 years: 306.27%
• Sector: Healthcare
• Industry: Biotechnology

About: Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Employees: 1,372

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

38% more funds holding in top 10

Funds holding in top 10: 8 [Q3] → 11 (+3) [Q4]

19% more first-time investments, than exits

New positions opened: 75 | Existing positions closed: 63

15% more call options, than puts

Call options by funds: $211M | Put options by funds: $184M

2.96% more ownership

Funds ownership: 90.04% [Q3] → 93.0% (+2.96%) [Q4]

1% more funds holding

Funds holding: 452 [Q3] → 456 (+4) [Q4]

0% less capital invested

Capital invested by funds: $10.7B [Q3] → $10.7B (-$28.9M) [Q4]

1% less repeat investments, than reductions

Existing positions increased: 155 | Existing positions reduced: 156

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $75 39% upside
• Avg. target: $118 119% upside
• High target: $183 240% upside

9 analyst ratings

• positive: 4 44%
• neutral: 4 44%
• negative: 1 11%

HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 57 / 186 met price target	39% upside $75	Neutral Reiterated	16 Apr 2025
Morgan Stanley Matthew Harrison 38% 1-year accuracy 9 / 24 met price target	238% upside $182	Overweight Maintained	11 Apr 2025
Wells Fargo Yanan Zhu 12% 1-year accuracy 2 / 17 met price target	114% upside $115	Overweight Initiated	11 Apr 2025
Needham Gil Blum 12% 1-year accuracy 19 / 157 met price target	240% upside $183	Buy Maintained	3 Apr 2025
RBC Capital Brian Abrahams 3% 1-year accuracy 2 / 66 met price target	62% upside $87	Sector Perform Downgraded	31 Mar 2025